Happy International Women’s Day. Best display of International Women’s day I’ve ever seen was in Russia when I was studying abroad. They took it SERIOUSLY. Not just a LinkedIn Holiday. Cat-astrophe? No, just a political speech – not reality. President Biden talked about increasing the number of negotiated drugs up to 50 a year. Not…
It has been fun to see the year really start to kick off this week with a bunch of policy releases. Shortages. Generic shortages are caused by a myriad of factors, but a big piece is the race to the bottom for prices. A fraction of a penny less and a contract shifts to another…
A thoughtful piece on price hikes. Price hikes are the routine story of January. Look price hikes! But because net price hides behind discounts and rebates, the full story is seldom in media. Here is a story that is (finally) a little more balanced on price hikes (and decreases). It even talks about the new…
One of my resolutions for this year is to get outside for a good walk every day. Get some air, get some steps, listen to a podcast. A break from work. Unless the podcast on money in university sports gets the thoughts spiraling to work parallels. Yesterday I was listening to the New York Time’s…
Give me time off and I’m likely to find myself in over my head with a project of my own making. #cantstopwontstop. Like deciding to bake 120 giant cookies and then deciding that I didn’t like the look of half of them and starting over. Health policy took a backseat to cookies and scones for…
We’re in that last work week before everyone dashes off. My own clients have headed for the hills (Short Hills?) and I’ve been baking and wrapping this week. It makes me appreciate the usual day to day of policy and reimbursement more than I would have thought. Next week I’ll pull out the vision boards…
Guess which one costs more. This Wall Street Journal article has been making the rounds this week. It highlights how if there are two prices for a drug, plans tend to prefer the higher cost one with higher rebates. I hesitate to call it news because it seems so obvious to those of us who…
InNOvation. Seagen said they aren’t looking at a drug that would treat early-stage bladder cancer because it would be subject to negotiation too soon after approval and wouldn’t have a financial return on the investment. Today the National Pharmaceutical Council published a great piece in Health Affairs that goes deeper into the subject of innovation…
I don’t know if anyone reading this has kids but, in my experience, my kid will start to stretch the boundary on behavior. Small at first. Then three weeks later I realize that everything has gone off the rails and I have to pull in the reigns. It feels like a rubber band that has…
Last week we covered 340B basics. If you missed it, here is a quick summary: There are hospitals, clinics, etc. that serve uninsured individuals. To help care for these patients, the 340B program requires pharmaceutical manufacturers (that wish to participate in the Medicaid program) to sell their products at a massive discount that the entities…